(iii) The clinical trials in non-small cell lung cancer have utilised HGF or c-Met inhibition exclusively to inhibit this pathway (generally in combination with an epidermal growth factor receptor inhibitor). The gene discussed is MET; the disease is non-small cell lung carcinoma.